ArticleJournal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing2023
Transient left bundle branch block associated with favipiravir treatment for coronavirus infection.
Article in Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
- Favipiravir-induced bradycardia: A case report.Clinical case reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coronavirus disease 2019 (COVID-19) may lead to a wide spectrum of clinical manifestations ranging from asymptomatic to symptomatic by having targets on various tissues such as lung parenchyma and myocardium (Shahrbaf et al., Cardiovasc Hematol Disord Drug Targets. 21(2):88-90, 2021). As an RNA-dependent RNApolymerase inhibitor, favipiravir has been proposed as a treatment in clinical studies done during the pandemic period (Furuta et al., Antiviral Res. 100(2):446-454, 2013). Although favipiravir is generally a safe medication, it may rarely cause cardiac adverse effects (Shahrbaf et al., Cardiovasc Hematol Disord Drug Targets. 21(2):88-90, 2021). To the best of our knowledge, favipiravir has not been reported to cause left bundle branch block (LBBB).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.